



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	352563	IM Repair
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	FIT-BioCeuticals Limited	
<b>Postal Address</b>	PO Box 6454, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	6/01/2021	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . IM Repair

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	15/02/2022
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Traditionally used in Western herbal medicine to demulcent/soothe irritated tissues

Traditionally used in Western herbal medicine to helps decrease/reduce/relieve symptoms of mild gastritis

Traditionally used in Western herbal medicine to helps decrease/reduce/relieve mild gastrointestinal tract inflammation

### Indication Requirements

Product presentation must only refer to mild gastritis.

Label statement: If symptoms persist, talk to your health professional.

Label statement: If symptoms persist or worsen talk to your medical practitioner.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

Not recommended for use by pregnant and lactating women (or words to that effect).

Adults only.

### Additional Product information

### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

### Components

#### 1 . Formulation 1

**Dosage Form** Powder, oral

**Route of Administration** Oral

**Visual Identification**

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Active Ingredients**

<b>Aloe vera leaf inner Juice dry</b>	<b>500 microgram/g</b>
Equivalent: Aloe vera (Juice fresh)	100 mg/g
<b>Althaea officinalis root Extract dry concentrate</b>	<b>150 mg/g</b>
Equivalent: Althaea officinalis (Dry)	637.5 mg/g
<b>Cinnamomum cassia stem bark Extract dry concentrate</b>	<b>13.34 mg/g</b>
Equivalent: Cinnamomum cassia (Dry)	200 mg/g
<b>glutamine</b>	<b>400 mg/g</b>
<b>glutathione</b>	<b>5 mg/g</b>
<b>Glycyrrhiza glabra root Extract dry concentrate standardised</b>	<b>15 mg/g</b>
Equivalent: Glycyrrhiza glabra (Dry)	412.5 mg/g
<b>pectin</b>	<b>20 mg/g</b>
<b>quercetin dihydrate</b>	<b>4.25 mg/g</b>
<b>Ulmus rubra stem bark inner Powder</b>	<b>100 mg/g</b>

**Other Ingredients (Excipients)**

colloidal anhydrous silica  
Flavour  
lecithin  
maltodextrin

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary